The company said, “We are raising our revenue guidance to at least 19% growth, or $222.8M for the full year. We continue to expect gross margin for the year to be in the range of 73% to 75%. This range reflects one-time costs, mainly related to an anticipated Avance Nerve Graft BLA approval, which we expect will negatively impact gross margin by approximately 1%, or $2M. Lastly, we reiterate that we expect to be net cash flow positive for the full year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.